APAC Endoscopic Bariatric Therapies Market Industry Trends and Forecast to 2034: Segmented by (Procedure, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$158.2 MnPlaceholder estimate
Estimate 2025$179.2 Mn23.8% of the global market
Projected 2034$551.3 Mn 207.7%Adds $372.1 Mn over 9 forecast years
CAGR 2025–203413.3%Faster than 76% of 186 Medical Devices markets here
Key players5
APAC is 23.81% of the global market.
Among regions, the largest is North America at $417.7 Mn.
Boston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics, Olympus Corporation (see all)
Active clinical trials
6 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Endoscopic Bariatric Therapies Market Analysis Executive Summary
Endoscopic bariatric therapies are weight-loss procedures done through the mouth with a flexible scope, without cuts in the skin.
Key segments of the endoscopic Bariatric Therapies market include procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon and Duodenal Mucosal Resurfacing) and product (Suturing Systems, Balloons and Liners).
Asia Pacific Endoscopic Bariatric Therapies market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the endoscopic Bariatric Therapies market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the endoscopic Bariatric Therapies market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Endoscopic Bariatric Therapies Market in APAC
The endoscopic Bariatric Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Endoscopic Bariatric Therapies Market in APAC
Endoscopic Bariatric Therapies in APAC: rules, payment and research
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], Ministry of Health (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Ministry of Health (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28]. ClinicalTrials.gov lists 6 studies on Endoscopic Bariatric Therapies that are recruiting, active or about to start in APAC.[29]
[29]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how endoscopic Bariatric Therapies products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Procedure
4.2 By Product
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Boston Scientific
7.2 Apollo Endosurgery
7.3 Fractyl Health
7.4 GI Dynamics
7.5 Olympus Corporation
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The endoscopic Bariatric Therapies market can be segmented based on various criteria, including procedure, product and end user. Here's a breakdown of the market segmentation
What doctors and scientists are doing in Endoscopic Bariatric Therapies right now, from free public sources.
Clinical trials
6 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Endoscopic Bariatric Therapies market in Asia Pacific?
Placeholder estimate: about $179.2 Mn in 2025, rising to about $551.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Endoscopic Bariatric Therapies market in Asia Pacific growing?
Placeholder estimate: about 13.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Endoscopic Bariatric Therapies market report cover?
The report splits the market by procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon, Duodenal Mucosal Resurfacing, Aspiration Therapy), product (Suturing Systems, Balloons, Liners) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Endoscopic Bariatric Therapies market?
Key players include Boston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics and Olympus Corporation.
What is driving the Endoscopic Bariatric Therapies market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market.
How many clinical trials on Endoscopic Bariatric Therapies are running in Asia Pacific?
6 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Endoscopic Bariatric Therapies?
PubMed lists 81 papers on Endoscopic Bariatric Therapies added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.